Results 21 to 30 of about 644,957 (254)

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics [PDF]

BioDiscovery, 2013
Inactivation of the function of tumor suppressor p53 is common in human cancers. In approximately half of human cancers, the tumor suppressor function of p53 is inactivated by deletion or mutation of TP53, the gene encoding p53 protein.
Yujun Zhao, Denzil Bernard, Shaomeng Wang   +2 more
doaj   +3 more sources

Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells

Molecules, 2022
MDM2 and MDM4 are cancer drug targets validated in multiple models for p53-based cancer therapies. The RING domains of MDM2 and non-p53-binder MDM2 splice isoforms form RING domain heterodimer polyubiquitin E3 ligases with MDM4, which regulate p53 ...
Rati Lama, Samuel L. Galster, Chao Xu, Luke W. Davison, Sherry R. Chemler, Xinjiang Wang   +5 more
doaj   +1 more source

MDM2- an indispensable player in tumorigenesis [PDF]

, 2023
Murine double minute 2 (MDM2) is a well-recognized molecule for its oncogenic potential. Since its identification, various cancer-promoting roles of MDM2 such as growth stimulation, sustained angiogenesis, metabolic reprogramming, apoptosis evasion ...
Zafar, Aasma, Khan, Muhammad Jawad, Naeem, Aisha, Aisha Naeem, Muhammad Jawad Khan, Aasma Zafar, Aasma Zafar (17785652), Aisha Naeem (14157078), Muhammad Jawad Khan (6909224)   +8 more
core   +1 more source

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer

Frontiers in Oncology, 2021
With the adoption of inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6i) in combination with endocrine therapy as standard of care for the treatment of advanced and metastatic estrogen receptor positive (ER+) breast cancer, the search is now on for ...
Neil Portman, Neil Portman, Julia Chen, Julia Chen, Elgene Lim, Elgene Lim   +5 more
doaj   +1 more source

MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4 [PDF]

, 2015
Melanoma antigen A (MAGE-A) proteins comprise a structurally and biochemically similar sub-family of Cancer/Testis antigens that are expressed in many cancer types and are thought to contribute actively to malignancy.
Susan E. Bray (264528), Thompson, Alastair M., Hourihan John, Quinlan Philip R., Philip R. Quinlan (743773), Thompson Alastair M., Meek, David W., Alastair M. Thompson (743775), Meek, David W, Marcar Lynnette, Lee B. Jordan (743774), Ihrig Bianca, David W Meek, Ted R. Hupp (141798), Hupp Ted R., Ihrig, Bianca, Hourihan, John, Meek David W., Bray Susan E., Thompson, Alastair M, Quinlan, Philip R., Susan E Bray, Lynnette Marcar (743770), Hupp, Ted R., John Hourihan, Philip R Quinlan, Jordan, Lee B., Bray, Susan E, Ted R Hupp, Lynnette Marcar, Quinlan, Philip R, David W. Meek (743776), Jordan Lee B., Alastair M Thompson, Marcar, Lynnette, Bianca Ihrig, John Hourihan (743772), Hupp, Ted R, Bray, Susan E., Lee B Jordan, Bianca Ihrig (743771), Jordan, Lee B   +41 more
core   +2 more sources

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]

, 2014
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
J Das, S Menendez, Menendez, S., Saville, M. K., S Dayal, Das, J., M K Saville, Dayal, S., A Sparks, Robertson, P., P Robertson, Sparks, A.   +11 more
core   +1 more source

MDM2 negatively regulates the human telomerase RNA gene promoter [PDF]

, 2005
<b>Background:</b> We have previously demonstrated that NF-Y and Sp1 interact with the human telomerase RNA (hTR) promoter and play a central role in its regulation. We have also shown that pRB activates the hTR promoter, but the mechanism
Jiangqin Zhao (6471), Keith, W.N., Katrina Jackson (6473), Bilsland, A., Jackson, K., Keith W Nicol, Alan Bilsland (6472), Zhao, J., Zhao Jiangqin, Bilsland Alan, Jackson Katrina, W. Nicol Keith (261494), Alan Bilsland, Katrina Jackson, Jiangqin Zhao, W Nicol Keith   +15 more
core   +2 more sources

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy

Frontiers in Oncology, 2021
Inhibition of the MDM2/X-p53 interaction is recognized as a potential anti-cancer strategy, including the treatment of glioblastoma (GB). In response to cellular stressors, such as DNA damage, the tumor suppression protein p53 is activated and responds ...
Xanthene Miles, Charlot Vandevoorde, Alistair Hunter, Julie Bolcaen   +3 more
doaj   +1 more source

Resistance acquisition to MDM2 inhibitors [PDF]

Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2).
Cinatl J, Speidel D, Hardcastle I, Michelis M   +3 more
core   +4 more sources

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers [PDF]

, 2006
BackgroundThe MDM2 gene encodes a negative regulator of the p53 tumour suppressor protein. A single nucleotide polymorphism (SNP) in the MDM2 promoter (a T to G exchange at nucleotide 309) has been reported to produce accelerated tumour formation in ...
Johnson, Peter W., White Helen E, Jeremy P Blaydes, Diana M Eccles, White, Helen E., Ellen R Copson, Johnson Peter W, Eccles Diana M, Eccles, Diana M., Helen E White, Robinson, David O., David O Robinson, Peter W Johnson, Blaydes, Jeremy P., Copson, Ellen R., Robinson David O, Copson Ellen R, Blaydes Jeremy P   +17 more
core   +2 more sources